Business Context and Reporting Period
This Form 8-K Current Report was filed by Damora Therapeutics, Inc. (DMRA) on April 28, 2026. The filing discloses significant changes to the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor effective May 1, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Lori Firmani ceased serving as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective May 1, 2026. She had held these roles since August 2024.
- Appointment of Successor: Brian Burkavage, previously Senior Vice President, Finance, was appointed as the new Principal Financial Officer and Principal Accounting Officer effective May 1, 2026.
- Separation Benefits: Ms. Firmani is entitled to separation benefits including a lump-sum payment of base salary continuation and pro-rated target bonus, a $6,000 health savings account contribution, and full acceleration of all outstanding equity awards, subject to the execution of a separation agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is that Ms. Firmani's separation benefits are subject to her execution and non-revocation of a separation agreement and general release of claims.
Investor Verification Checklist
- Verify the terms of the separation agreement and general release for Lori Firmani.
- Review the Definitive Proxy Statement on Schedule 14A filed April 28, 2026, for details on the Executive Separation Benefits Plan.
- Confirm the full acceleration of Ms. Firmani's equity awards and the impact on the Company's share count.
- Assess the transition plan for financial reporting responsibilities under the new Principal Accounting Officer, Brian Burkavage.